Author Archives | Simplyjo
Simplyjo - who has written 81 posts on FavStocks.
I have done by Post Graduation in Tourism from College of Vocational Studies apart from a full time MBA degree in Finance.I have worked with several reputed companies including IBM, MakeMyTrip and Habitat World.
I love to read, write and travel.
Currently, I am a SAHM ,earning a living off the stock market and making a killing with forex trades. I am sharing my knowledge so as to help others learn and expand their horizon.
Facet Biotech Reports Elotuzumab Data (NASDAQ:FACT)
Facet Biotech Corporation (NASDAQ:FACT) along with Bristol-Myers Squibb Company have announced that the interim data from the study of elotuzumab is promising.
Continue reading...Simulations Plus’ New Software Version (NASDAQ:SLP)
30 November 2009
Comments Off
Simulations Plus, Inc (NASDAQ:SLP) has announced that they have released the new version of GastroPlus state of the art software which is being used by many pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.
Continue reading...Healthways’ Fitness Program (NASDAQ:HWAY)
30 November 2009
Comments Off
Healthways, Inc. (NASDAQ:HWAY) and Physicians Health Choice together have announced an agreement to provide the Healthways SilverSneakers Fitness Program to eligible Physicians Health Choice plan members in Texas, Florida, Arkansas and New Mexico that will begin from the very first month in 2010.
Continue reading...ImmunoGen’s Second License to Amgen (IMGN, AMGN)
20 November 2009
Comments Off
ImmunoGen, Inc. (NASDAQ:IMGN) has announced that Amgen, Inc. (NASDAQ:AMGN)Inc has licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology for the development of anticancer therapeutics to an undisclosed target.
Continue reading...Sucampo Granted Marketing Authorization From FDA (NASDAQ:SCMP)
20 November 2009
Comments Off
Sucampo Pharma Europe Ltd, a subsidiary of Sucampo Pharmaceuticals Inc (NASDAQ:SCMP) has announced that Swissmedic has granted a marketing authorization for Amitiza 24 mcg gel capsules for the long term treatment of patients with chronic idiopathic constipation (CIC).
Continue reading...Exelixis PI3K Interim Data (NASDAQ:EXEL)
18 November 2009
Comments Off
Exelixis, Inc (NASDAQ:EXEL) has announced and reported that the interim data from an ongoing Phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid tumors have displayed positive results.
Continue reading...ArQule’s Drug Discovery Platform (NASDAQ:ARQL)
17 November 2009
Comments Off
ArQule Inc (NASDAQ:ARQL) has presented their data at the AACR-NCI-EORTC meeting in Boston which clearly demonstrates the capabilities of Company’s proprietary drug discovery platform to generate a class of small molecules that has significant therapeutic potential.
Continue reading...Mach One’s Co-Development Plans (OTC:MNCN)
17 November 2009
Mach One Corporation (OTC:MNCN) has announced that they have completed the first tranche of their investment in PanTheryx, Inc. as stipulated in the recent Letter of Understanding signed in August 2009.
Continue reading...Vivakor Regeneca Agreement (OTC:VIVK)
12 November 2009
Comments Off
Vivakor, Inc (OTC:VIVK) announced that they have successfully completed an exclusive distribution agreement with consumer product specialist, Regeneca International, Inc.
Continue reading...Metabolix Prices Public Offering (NASDAQ:MBLX)
12 November 2009
Comments Off
Metabolix Inc (NASDAQ:MBLX) have announced that they have priced a public offering of 3.0 million new issued shares of its common stock at a public offering price of US$9.00 per share.
Continue reading...
8 December 2009
Comments Off